Deep learning platform (AtomNet) for structure-based small molecule drug discovery. Screens trillions of compounds against disease targets. 250+ research partnerships.
AtomNet's ability to screen billions of compounds in hours (vs. years) is the core value proposition. Strong track record across oncology, neurology, and infectious diseases.
Federated learning AI platform for biomedical research. Trains AI models on sensitive hospital data without compromising privacy. Focuses on oncology and patient stratification.
End-to-end AI drug discovery platform (Pharma.AI). One of the first companies to have an AI-designed drug enter human clinical trials. Focuses on oncology and fibrosis.
Genomics’ Mystra is an AI-enabled human genetics platform for drug target discovery and validation, offered with self-serve SaaS and managed options.
AI-first drug discovery company combining biological imaging, machine learning, and automated labs to identify therapeutic candidates at scale. Partnerships with Bayer and Roche.